Arvinas (ARVN) Other Non-Current Assets (2017 - 2026)
Arvinas (ARVN) posted quarterly Other Non-Current Assets of $3.5 million for Q1 2026, down 27.08% year-over-year from $4.8 million in Q1 2025, and down 7.89% quarter-over-quarter from $3.8 million in Q4 2025.
Arvinas (ARVN) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Arvinas' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $3.5 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 27.08% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $3.5 million (down 27.08% YoY), while the FY2025 annual figure was $3.8 million, down 53.09% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $3.5 million, down from $3.8 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $12.1 million in Q1 2022, with the low at $3.5 million in Q1 2026.
- The 5-year median for Other Non-Current Assets is $9.9 million (2024), against an average of $8.6 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets rose 14.85% in 2024, then sank 62.07% in 2025.
- Arvinas' Other Non-Current Assets stood at $10.8 million in 2022, then declined by 3.7% to $10.4 million in 2023, then decreased by 22.12% to $8.1 million in 2024, then sank by 53.09% to $3.8 million in 2025, then slipped by 7.89% to $3.5 million in 2026.
- Business Quant data shows ARVN's Other Non-Current Assets at $3.5 million in Q1 2026, $3.8 million in Q4 2025, and $3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | 10.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.60 Mn |
| Mar 31, 2026 | 3.50 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Sep 30, 2025 | 3.90 Mn |
| Jun 30, 2025 | 4.40 Mn |
| Mar 31, 2025 | 4.80 Mn |
| Dec 31, 2024 | 8.10 Mn |
| Sep 30, 2024 | 9.80 Mn |
| Jun 30, 2024 | 11.60 Mn |
| Mar 31, 2024 | 9.90 Mn |
| Dec 31, 2023 | 10.40 Mn |
| Sep 30, 2023 | 9.60 Mn |
| Jun 30, 2023 | 10.10 Mn |
| Mar 31, 2023 | 10.30 Mn |
| Dec 31, 2022 | 10.80 Mn |
| Sep 30, 2022 | 11.30 Mn |
| Jun 30, 2022 | 11.70 Mn |
| Mar 31, 2022 | 12.10 Mn |
| Dec 31, 2021 | 12.50 Mn |
| Sep 30, 2021 | 12.84 Mn |